Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: Implications for prognosis and staging

References

• Vonderheid E C, Bernengo M G, Burg G, Duvic M, Heald P, Laroche L, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95–106
   PubMed Web of Science ®Google Scholar
• Vonderheid E C, Bernengo M G. The Sézary syndrome: hematologic criteria. Hematol Oncol Clin N Am 2003; 17: 1367–1389
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe E S, Burg G, Cerroni L, Berti E, Swerdlow S H, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–3785
   PubMed Web of Science ®Google Scholar
• Sézary A, Bouvrain Y. Erythrodermie avec présence de cellules monstrueuses dans le derme et le sang circulant. Bull Soc Fr Derm Syph 1938; 45: 254–260
   Google Scholar
• Lutzner M A, Jordan H W. The ultrastructure of an abnormal cell in Sézary's syndrome. Blood 1968; 31: 719–726
   PubMed Web of Science ®Google Scholar
• Lutzner M A, Hobbs J W, Horvath P. Ultrastructure of abnormal cells in Sézary syndrome, mycosis fungoides, and parapsoriasis en plaque. Arch Dermatol 1971; 103: 375–386
   PubMed Web of Science ®Google Scholar
• Flandrin G, Brouet J C. The Sézary cell: cytologic, cytochemical, and immunologic studies. Mayo Clin Proc 1974; 49: 575–583
   PubMed Web of Science ®Google Scholar
• Meyer C JLM, van Leeuwen A WFM, van der Loo E M, van de Putte L BA, van Vloten W A. Cerebriform (Sézary like) mononuclear cells in healthy individuals: a morphologically distinct population of T cells. Virchows Arch B Cell Pathol 1977; 25: 95–104
   PubMedGoogle Scholar
• Weinberg J M, Jaworsky C, Benoit B M, Telegan B, Rook A H, Lessin S R. The clonal nature of circulating Sézary cells. Blood 1995; 86: 4257–4262
   PubMed Web of Science ®Google Scholar
• Preesman A H, Schrooyen S J, Toonstra J, van der Putte S CJ, Rademakers L HPM, Willemze R, et al. The diagnostic value of morphometry on blood lymphocytes in erythrodermic actinic reticuloid. Arch Dermatol 1995; 131: 1298–1303
   PubMed Web of Science ®Google Scholar
• Litovitz T L, Lutzner M A. Quantitative measurements of blood lymphocytes from patients with chronic lymphocytic leukemia and the Sézary syndrome. J Natl Cancer Inst 1974; 53: 75–77
   PubMed Web of Science ®Google Scholar
• Reinhold U, Herpertz M, Kukel S, Oltermann I, Uerlich M, Kreysel H W. Induction of nuclear contour irregularity during T-cell activation via the T-cell receptor/CD3 complex and CD2 antigens in the presence of phorbol esters. Blood 1994; 83: 703–706
   PubMed Web of Science ®Google Scholar
• Winkelmann R K, Linman J W. Erythroderma with atypical lymphocytes (Sézary syndrome). Am J Med 1973; 55: 192–198
   PubMed Web of Science ®Google Scholar
• Winkelmann R K. Clinical studies of T-cell erythroderma in the Sézary syndrome. Mayo Clin Proc 1974; 49: 519–525
   PubMed Web of Science ®Google Scholar
• Winkelmann R K, Hoagland H C. The Sézary cell in the blood of patients with mycosis fungoides. Dermatologica 1980; 160: 73–79
   PubMedGoogle Scholar
• Winkelmann R K, Peters M S. Absolute number of circulating Sézary cells [letter]. Arch Dermatol 1981; 117: 382
   PubMed Web of Science ®Google Scholar
• Winkelmann R K, Buechner S A, Diaz-Perez J L. Pre-Sézary syndrome. J Am Acad Dermatol 1984; 10: 992–999
   PubMed Web of Science ®Google Scholar
• Buechner S A, Winkelmann R K. Pre-Sézary erythroderma evolving to Sezary syndrome. A report of seven cases. Arch Dermatol 1983; 119: 285–291
   PubMed Web of Science ®Google Scholar
• Lutzner M, Edelson R, Schein P, Green I, Kirkpatrick C, Ahmed A. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 1975; 83: 534–552
   PubMed Web of Science ®Google Scholar
• Willemze R, van Vloten W A, Hermans J, Damsteeg M JM, Meijer C JLM. Diagnostic criteria in Sézary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. J Invest Dermatol 1983; 81: 392–397
   PubMed Web of Science ®Google Scholar
• Vonderheid E C, Sobel E L, Nowell P C, Finan J B, Helfrich M K, Whipple D S. Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T cell lymphoma. Blood 1985; 66: 358–366
   PubMed Web of Science ®Google Scholar
• Schechter G P, Sausville E A, Fischmann A B, Soehnlen F, Eddy J, Matthews M, et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood 1987; 69: 841–849
   PubMed Web of Science ®Google Scholar
• Toonstra J, van Weelden H, Gmelig Meyling F H, van der Putte S C, Schiere S I, Baart de la Faille H. Actinic reticuloid simulating Sézary syndrome. Report of two cases. Arch Dermatol Res 1985; 277: 159–166
   PubMed Web of Science ®Google Scholar
• D'Incan M, Souteyrand P, Bignon Y J, Fonck Y, Roger H. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sézary syndrome. Arch Dermatol 1992; 128: 1371–1374
   PubMed Web of Science ®Google Scholar
• Sausville E A, Eddy J L, Makuch R W, Fischmann A B, Schechter G P, Matthews M, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups. Ann Intern Med 1988; 109: 372–382
   PubMed Web of Science ®Google Scholar
• Toro J R, Stoll H L, Jr, Stomper P C, Oseroff A R. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 1997; 37: 58–67
   PubMed Web of Science ®Google Scholar
• Bernengo M G, Quaglino P, Novelli M, Cappello N, Doveil G C, Lisa F, et al. Prognostic factors in Sezary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 1998; 9: 857–863
   PubMed Web of Science ®Google Scholar
• Wang S, Li N, Heald P, Fisk J M, Fadare O, Howe J G, et al. Flow cytometric DNA ploidy analysis of peripheral blood from patients with sezary syndrome: detection of aneuploid neoplastic T cells in the blood is associated with large cell transformation in tissue. Am J Clin Pathol 2004; 122: 774–782
   PubMed Web of Science ®Google Scholar
• Scarisbrick J J, Whittaker S, Evans A V, Fraser-Andrews E A, Child F J, Dean A, et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001; 97: 624–630
   PubMed Web of Science ®Google Scholar
• Wasik M A, Vonderheid E C, Bigler R D, Marti R, Lessin S R, Polansky M, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996; 132: 42–47
   PubMed Web of Science ®Google Scholar
• Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 1999; 40: 914–924
   PubMed Web of Science ®Google Scholar
• Foulc P, N'Guyen J M, Dreno B. Prognostic factors in Sézary syndrome: a study of 28 patients. Br J Dermatol 2003; 149: 1152–1158
   PubMed Web of Science ®Google Scholar
• Tancrede-Bohin E, Ionescu M A, de La Salmoniere P, Dupuy A, Rivet J, Rybojad M, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol 2004; 140: 1057–1061
   PubMed Web of Science ®Google Scholar
• Nowell P C, Finan J B, Vonderheid E C. Clonal characteristics of cutaneous T cell lymphomas: cytogenetic evidence from blood, lymph nodes, and skin. J Invest Dermatol 1982; 78: 69–75
   PubMed Web of Science ®Google Scholar
• Bunn P A, Jr, Lamberg S I. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 725–728
   PubMedGoogle Scholar
• Kim Y H, Bishop K, Varghese A, Hoppe R T. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995; 131: 1003–1008
   PubMed Web of Science ®Google Scholar
• Marti R M, Pujol R M, Servitje O, Palou J, Romagosa V, Bordes R, et al. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma 2003; 44: 59–69
   PubMed Web of Science ®Google Scholar
• Jacyk W K, Ungerer J P. Serum lactate dehydrogenase activity in exfoliative dermatitis. J Dermatol 1991; 18: 743
   PubMedGoogle Scholar
• Sausville E A, Worsham G F, Matthews M J, Makuch R W, Fischmann A B, Schechter G P, et al. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985; 16: 1098–1109
   PubMed Web of Science ®Google Scholar
• Lutzner M A, Emerit I, Durepaire R, Flandrin G, Grupper C, Prunieras M. Cytogenetic, cytophotometric, and ultrastructural study of large cerebriform cells of the Sézary syndrome and description of the small-cell variant. J Natl Cancer Inst 1973; 50: 1145–1162
   PubMed Web of Science ®Google Scholar
• Heald P, Yan S L, Edelson R. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 1994; 130: 198–203
   PubMed Web of Science ®Google Scholar
• Vonderheid E C, Boselli C M, Conroy M, Casaus L, Espinoza L C, Venkataramani P, et al. Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma. J Invest Dermatol 2005; 124: 651–661
   PubMed Web of Science ®Google Scholar
• Kuchnio M, Sausville E A, Jaffe E S, Greiner T, Foss F M, McClanahan J, et al. Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression. Am J Clin Pathol 1994; 102: 856–560
   PubMed Web of Science ®Google Scholar
• Edelman J, Meyerson H J. Diminished CD3 expression is useful for detecting and enumerating Sézary cells. Am J Clin Pathol 2000; 114: 467–477
   PubMed Web of Science ®Google Scholar
• Washington L T, Huh Y O, Powers L C, Duvic M, Jones D. A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol 2002; 2: 5–12
   PubMedGoogle Scholar
• Bogen S A, Pelley D, Charif M, McCusker M, Koh H, Foss F, et al. Immunophenotypic identification of Sézary cells in peripheral blood. Am J Clin Pathol 1996; 106: 739–748
   PubMed Web of Science ®Google Scholar
• Harmon C B, Witzig T E, Katzmann J A, Pittelkow M R. Detection of circulating T cells with CD4 + CD7− immunophenotype in patients with benign and malignant lymPphoproliferative dermatoses. J Am Acad Dermatol 1996; 35: 404–410
   PubMed Web of Science ®Google Scholar
• Bernengo M G, Novelli M, Quaglino P, Lisa F, De Matteis A, Savoia P, et al. The relevance of the CD4 + CD26− subset in the identification of circulating Sézary cells. Br J Dermatol 2001; 144: 125–135
   PubMed Web of Science ®Google Scholar
• Jones D, Dang N H, Duvic M, Washington L T, Huh Y O. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001; 115: 885–892
   PubMed Web of Science ®Google Scholar
• Lima M, Almeida J, dos Anjos Teixeira M, Queiros M L, Santos A H, Fonseca S, et al. Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4 + Sézary's syndrome. Haematologica 2003; 88: 874–887
   PubMed Web of Science ®Google Scholar
• Poszepczynska-Guigne E, Schiavon V, D'Incan M, Echchakir H, Musette P, Ortonne N, et al. CD158k/KIR3DL2 is a new phenotypic marker of Sézary cells: relevance for the diagnosis and follow-up of Sézary syndrome. J Invest Dermatol 2004; 122: 820–823
   PubMed Web of Science ®Google Scholar
• Burke J S, Colby T V. Dermatopathic lymphadenopathy. Comparison of cases associated and unassociated with mycosis fungoides. Am J Surg Pathol 1981; 5: 343–352
   PubMed Web of Science ®Google Scholar
• Vonderheid E C, Diamond L W, van Vloten W A, Scheffer E, Meijer C J, Cashell A W, et al. Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the Working Formulation of Non-Hodgkin's Lymphomas for Clinical Usage. Cancer 1994; 73: 207–218
   PubMed Web of Science ®Google Scholar
• Bakels V, Van Oostveen J W, Geerts M L, Gordijn R L, Walboomers J M, Scheffer E, et al. Diagnostic and prognostic significance of clonal T-cell receptor beta gene rearrangements in lymph nodes of patients with mycosis fungoides. J Pathol 1993; 170: 249–255
   PubMed Web of Science ®Google Scholar
• Kern D E, Kidd P G, Moe R, Hanke D, Olerud J E. Analysis of T-cell receptor gene rearrangement in lymph nodes of patients with mycosis fungoides. Prognostic implications. Arch Dermatol 1998; 134: 158–164
   PubMed Web of Science ®Google Scholar
• Breneman D L, Raju U S, Breneman J C, Steele P E, McFadden D W, Cualing H D, et al. Lymph node grading for staging of mycosis fungoides may benefit from examination of multiple excised lymph nodes. J Am Acad Dermatol 2003; 48: 702–706
   PubMed Web of Science ®Google Scholar
• Galindo L M, Garcia F U, Hanau C A, Lessin S R, Jhala N, Bigler R D, et al. Fine-needle aspiration biopsy in the evaluation of lymphadenopathy associated with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome). Am J Clin Pathol 2000; 113: 865–871
   PubMed Web of Science ®Google Scholar
• Sigurdsson V, Toonstra J, Hezemans-Boer M, van Vloten W A. Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol 1996; 35: 53–57
   PubMed Web of Science ®Google Scholar
• Axelrod P I, Lorber B, Vonderheid E C. Infections complicating mycosis fungoides and Sezary syndrome. JAMA 1992; 267: 1354–1358
   PubMed Web of Science ®Google Scholar
• Kantor A F, Curtis R E, Vonderheid E C, van Scott E J, Fraumeni J F, Jr. Risk of second malignancy after cutaneous T-cell lymphoma. Cancer 1989; 63: 1612–1615
   PubMed Web of Science ®Google Scholar
• Scarisbrick J S, Child F C, Evans A V, Fraser-Andrews E A, Spittle M, Russell-Jones R. Secondary malignant neoplasms in 71 patients with Sézary syndrome. Arch Dermatol 1999; 135: 1381–1385
   PubMed Web of Science ®Google Scholar
• Green S B, Byar D P, Lamberg S I. Prognostic variables in mycosis fungoides. Cancer 1981; 47: 2671–2677
   PubMed Web of Science ®Google Scholar
• Shipp M A. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has ‘high-risk’ disease?. Blood 1994; 83: 1165–1173
   PubMed Web of Science ®Google Scholar
• Bernengo M G, Fierro M T, Novelli M, Lisa F, Appino A. Soluble interleukin-2 receptor in Sézary syndrome: its origin and clinical application. Br J Dermatol 1993; 128: 124–129
   PubMed Web of Science ®Google Scholar
• Kari L, Loboda A, Nebozhyn M, Rook A H, Vonderheid E C, Nichols C, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197: 1477–1488
   PubMed Web of Science ®Google Scholar
• Klemke C D, Mansmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 2005; 153: 118–124
   PubMed Web of Science ®Google Scholar
• Fraser-Andrews E A, Russell-Jones R. Woolford AJ, Wolstencroft RA, Dean AJ, Whittaker SJ. Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sézary syndrome. Cancer 2001; 92: 1745–1752
   PubMed Web of Science ®Google Scholar